Pricing
  1. JP-listed companies
  2. TAKARA BIO INC.
  3. Financials
  4. Property, plant and equipment, net

TAKARA BIO INC.【JP:4974】

Market cap
¥138.1B
P/E ratio
-15.3x
Takara Bio develops and manufactures biotechnology products including research reagents, PCR instruments, and gene therapy treatments for universities, research institutions, and companies worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndProperty, plant and equipment, net (Million JPY)YoY (%)
Mar 31, 202556,954+16.06%
Mar 31, 202449,075+19.82%
Mar 31, 202340,956+12.53%
Mar 31, 202236,395+22.27%
Mar 31, 202129,766+22.93%
Mar 31, 202024,213+13.12%
Mar 31, 201921,404+15.49%
Mar 31, 201818,534-5.33%
Mar 31, 201719,577-4.66%
Mar 31, 201620,534+0.01%
Mar 31, 201520,532

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)